Conference Reports for NATAP

Back

AASLD American Association For The Study of Liver Diseases November 11-15, 2005 San Francisco     Hepatitis B Articles   Pharmacokinetics, Safety, and Tolerability of the Isatoribine Oral Prodrug ANA975 in a Phase I Heakthy Volunteer Study (12/14/05)   Double-Dose Peginterferon Alfa-2b with weight-Based Ribavirin Improves Response for Interferon/Ribavirin Non-Responders with Hepatitis C: Final Results of RENEW Study (12/14/05)   Safety of Double Dose Pegasys (REPEAT Study) (12/12/05)   24 Week Pegasys+RBV Treatment SVR in Genotype 1 Predicted by Wk 4 Response (12/07/05)   24 Week Pegasys + RBV for Genotype 1: SVR predicted by week 4 response (12/07/05)   Pradefovir, New HBV Drug: 24 Wks (12/05/05)   5 Years Adefovir in HBeAg-Negatives (12/05/05)   Clevudine, new HBV Drug: 24 week study results (12/05/05)   Long-term effect of tenofovir in the treatment of lamivudine-resistant HBV in comparison to adefovir (12/02/05)   Normal ALT & Low HBV-DNA May Be Risk for Cirrhosis & HCC (11/28/05)   Serum Leptin Level Associated with Severity of Liver Fibrosis & Decreased After Pegasys Treatment in Chronic Hepatitis B (11/28/05)   Low Rate of Viral Rebound Seen in HBV Patients Treated With Entecavir (11/28/05)   Entecavir 2 Years Study Results in HBeAg+ HBV+ Patients (study ETV-22) (11/16/05)   Five-Year Data Evaluating Long-Term Therapy with Hepsera for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Presented at AASLD Annual Meeting (11/15/05)   SEVERE IMPAIRMENT IN QUALITY OF LIFE IN HIV+ WITH HCV BUT NOT WITH HBV (11/14/05)   BARACLUDE (entecavir) TWO-YEAR DATA ANALYSIS DID NOT DETECT EMERGENCE OF RESISTANCE IN NUCLEOSIDE-NAIVE CHRONIC HEPATITIS B PATIENTS (11/14/05)   HEPATITIS B: SCIENCE & TREATMENT 2005 (11/11/05)     Hepatitis C Articles   Safety & Efficacy of Schering HCV Protease Inhibitor + Peg-Intron for Genotype 1 Non-responders to Peginterferon/ribavirin, with & without Ribavirin Phase II Study (02/24/06)   Study Finds EPO Improved SVR Only in High Dose RBV Group (02/01/06)   WIN-R Study: final results of Weight-Based dosing study of ribavirin in treatment-naive patients (01/31/06)   Double-Dose Peginterferon Alfa-2b with weight-Based Ribavirin Improves Response for Interferon/Ribavirin Non-Responders with Hepatitis C: Final Results of RENEW Study (12/14/05)   Five Million Americans Infected with the Hepatitis C Virus: A Corrected Estimate (12/02/05)   A Phase 2 Study of Albuferon in Combination with Ribavirin in non-responders to proir interferon therapy for chronic Hepatitis C (11/28/05)   NM283 +Pegasys for Nonresponders: phase II 12 weeks (11/28/05)   Consensus IFN+ IFN Gamma-1b in African-American Peg Nonresponders (11/28/05)   Consensus Interferon + Ribavirin SVRs in Coinfected (11/28/05)   Consensus Interferon: study results at AASLD (11/17/05)   Albuferon-Alpha (Albumin-Interferon Alpha) (11/17/05)   REPEAT Study: Non-responders to ≥12 weeks' treatment with standard-dose pegylated interferon alfa-2b (PegIntron) plus ribavirin received standard dose of Pegasys + ribavrin or double dose Pegasys + ribavirin (11/15/05)   Albuferon + Ribavirin in PegIFN Nonresponders: phase 2 study (11/15/05)   SCH 503034 HCV Protease Inhibitor Monotherapy in HCV Genotype 1 IFN Nonresponders (11/15/05)   VX-950 Hep C Protease Inhibitor (11/15/05)   Combination therapy with SCH-503034 HCV Protease Inhibitor & PegIntron in Non-Responders: phase !b study results (11/15/05)   Liver Transplant Articles AASLD (11/14/05)   Study Evaluations of Non-Invasive Fibrosis Tests AASLD (11/14/05)   Combination therapy with SCH-503034 HCV Protease Inhibitor & PegIntron in Non-Responders: phase !b study results (11/15/05)   LIVER HISTOLOGY IN HEPATITIS C PATIENTS WITH NORMAL ALT LEVELS (11/14/05)   Hispanics Developed Cirrhosis More Quickly Due to the presence of Fatty Liver & Diabetes (11/14/05)   IMPACT OF CAFFEINE CONSUMPTION ON ALT AND HISTOLOGICAL ACTIVITY IN PATIENTS WITH CHRONIC ACTIVE HCV (11/14/05)   CANNABINOIDS BLOCK INTERFERON-MEDIATED SUPPRESSION OF HEPATITIS C VIRUS (HCV) REPLICATION (11/14/05)   CRYOGLOBULINEMIA IS ASSOCIATED WITH STEATOSIS AND FIBROSIS IN CHRONIC HCV (11/14/05)   INDEPENDENT VALIDATION AND COMPARISON WITH FIBROSCAN, FIBROTEST AND LIVER BIOPSY OF CLINICAL GLYCOMICS FOR THE NON INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV (11/14/05)   COST-EFFECTIVENESS OF TREATMENT FOR CHRONIC HCV IN PATIENTS COINFECTED WITH HIV (11/14/05)   COFFEE DRINKING DECREASES THE RISK OF CHRONIC LIVER DISEASE IN THE UNITED STATES POPULATION (11/14/05)   African-American patients had fewer office visits and were less likely to return for a second office visit (11/14/05)   VIROLOGICAL AND HISTOLOGICAL FEATURES OF HCV IN PATIENTS WITH NORMAL ALT: RESULTS OF A TEN YEAR PROPSECTIVE FOLLOW-UP STUDY (11/14/05)   FIVE MILLION AMERICANS INFECTED WITH THE HEPATITIS C VIRUS: A CORRECTED ESTIMATE (11/14/05)   2.2% Liver Cancer developed Among SVRs; Sexual Dysfunction among HCV+ (11/14/05)   Telbivudine (LdT) Phase 3 One Year Study Results (11/14/05)   FIBROSCAN, MONITORING LIVER STIFFNESS: A NEW TOOL TO MEASURE LIVER FIBROSIS DURING THERAPY (11/14/05)   IS LIVER BIOPSY JUSTIFIED IN HEPATITIS C GENOTYPE 2 AND 3? (11/14/05)   ON TREATMENT VIROLOGICAL RESPONSE OF 70% IN 100 PATIENTS TREATED WITH COMBINATION ANTIVIRAL THERAPY FOR RECURRENT HCV FOLLOWING LIVER TRANSPLANTATION (11/14/05)   MULTICENTER RANDOMIZED TRIAL OF HCV TREATMENT WITH PEGINTERFERON-ALFA 2A (Pegasys) AND RIBAVIRIN AFTER LIVER TRANSPLANTATION:ONE-YEAR REPORT (11/14/05)   RECURRENT HEPATITIS C IS A RISK FACTOR FOR POOR OUTCOME AFTER LIVER RETRANSPLANTATION (11/14/05)   PREDICTING OUTCOME IN PATIENTS WITH HCV AFTER OLT: A 15-YEARS FOLLOW-UP (11/14/05)   LONG TERM RESULTS AFTER THERAPY WITH PEGYLATED INTERFERON ALPHA 2A (PEGASYS) IN HCV POSITIVE LIVER TRANSPLANT RECIPIENTS (11/14/05)   THE PERFORMANCE OF APRI FOR THE DIAGNOSIS OF SIGNIFICANT HEPATIC FIBROSIS IS IMPROVED BY A SIMPLE MODIFICATION (11/14/05)   Diabetes Death & Complications May triple in Next 20 years (11/11/05)     HIV Articles   Troglitazone significantly reduced tumor growth in vivo, and caused tumor regression in liver cells (11/14/05)   24% with HCV Are HIV+ at NYC Hospitals Studied (11/14/05)   Liver Disease The Leading Cause of Death in HIV: Hepatitis screening campaign launched. AASLD Liver Conference Starts Nov 10 in SF (11/11/05)   EVIDENCE FOR SEXUAL TRANSMISSION OF HCV IN RECENT EPIDEMIC IN HIV-INFECTED MEN IN SOUTHEAST ENGLAND (11/14/05)